February, 2011

A Retrospective Analysis of the Clinical Quality Effects of the Acquisition of Highland Park Hospital by Evanston Northwestern Healthcare

Patrick S. Romano, University of California - Davis
David J. Balan, Federal Trade Commission

Available at: https://works.bepress.com/david_balan/9/
A Retrospective Analysis of the Clinical Quality Effects of the Acquisition of Highland Park Hospital by Evanston Northwestern Healthcare

PATRICK S. ROMANO and DAVID J. BALAN

ABSTRACT In 2004, the Federal Trade Commission brought a legal action retrospectively challenging the 2000 acquisition of Highland Park Hospital by Evanston Northwestern Healthcare in Evanston, Illinois. A major issue in that case was whether the merger had resulted in improved clinical quality at Highland Park. In this paper, we describe the conceptual framework that guided our analysis of that issue and we report our findings. Specifically, we examine numerous quantitative measures of clinical quality. We find little evidence that the merger improved quality. We also discuss the applicability of our framework to the prospective analysis of unconsummated hospital mergers.

Key Words: Hospital Mergers; Merger Retrospectives; Antitrust Enforcement; Health Care Quality.

JEL classifications: I10, L40.

1. Introduction

In 2004, the Federal Trade Commission (FTC) brought legal action retrospectively challenging the 2000 acquisition of Highland Park Hospital (HPH) by the Evanston Northwestern Healthcare (ENH) hospital system, which prior to the merger had consisted of Evanston Hospital and Glenbrook Hospital. All three hospitals are in

Patrick Romano served as the FTC’s testifying expert on the clinical quality effects of the Evanston Northwestern Healthcare/Highland Park Hospital merger. Balan is an FTC staff economist who worked with Romano on that case. We are grateful to Keith Brand, Daniel Hosken, David Schmidt, Steven Tenn, Joseph Farrell, Ted Frech and Michael Vita for helpful comments; to Peter Newberry, who did excellent work for the FTC as a Research Analyst during the trial, and to Jordan Rhodes, who provided excellent research assistance for this paper. The views expressed in this paper are those of the authors and do not represent the views of the Federal Trade Commission or of any individual Commissioner.

Patrick S. Romano, University of California, Davis, Division of General Medicine, 4150 V Street, PSSB Suite 2400, Sacramento, CA 95817; e-mail: psromano@ucdavis.edu. David J. Balan, Bureau of Economics, Federal Trade Commission, 600 Pennsylvania Avenue NW, Mail Drop NJ-4264, Washington, DC 20580; e-mail: dbalan@ftc.gov.
or near Evanston, Illinois. As discussed in Haas-Wilson and Garmon (2011), there is strong evidence that prices at the merging hospitals increased following the merger. Balan and Garmon (2008) discuss FTC Complaint Counsel’s interpretation of this price increase, and the alternative interpretation of Respondent’s Counsel.

Respondent’s Counsel claimed that the merger caused clinical quality at HPH to improve in several important ways. The main purpose of this paper is to describe the analyses that we performed in response to those claims. Our study deals with clinical quality, as it has been defined by the Institute of Medicine and the World Health Organization, and not with hospital amenities. Some of our analyses relied on confidential data provided by the merging parties, and so cannot be reported here. However, the central component of our evaluation used publicly available quality measures and data, which can be reported (see Romano and Mutter, 2004, for a detailed description of the variety of available measures of clinical quality). We find little evidence that the merger improved quality at HPH.

A secondary purpose of the paper is to lay out the conceptual framework that we believe should be applied in evaluating clinical quality claims in hospital merger cases, both retrospective and prospective. We discuss the basis for our prior belief that hospital mergers do not on average improve hospital quality, but are nevertheless likely enough to do so that substantial case-specific investigation is usually warranted. We also discuss the most likely sources of quality improvement and ways to evaluate them.

2. Conceptual Framework

2.1 Priors

Since the ENH/HPH case was retrospective, our primary evidence came from our difference-in-differences (DID) analyses, which we used to measure directly the effect of the merger on clinical quality. However, the strength of the direct evidence required to reach a conclusion regarding the effect of a particular merger depends on one’s prior beliefs regarding hospital mergers in general. For this reason, we briefly review the relevant research that informs our prior belief that, on average, hospital mergers do not substantially improve clinical quality.

As discussed in Gaynor (2006), the effect of reduced competition on quality (holding the cost of producing quality constant) is theoretically ambiguous when firms choose both price and quality. But when prices are fixed rather than chosen by the firm, optimal quality unambiguously decreases following a competition-reducing merger; absent the ability to raise price, the only way for the firm to benefit from reduced competition is by cutting quality and thereby reducing costs. After the merger the gain from a small reduction in quality (lower costs on retained sales) is the same as it was before, but the loss from doing so (reduced sales) is smaller because the residual demand has become less elastic. Therefore, the pre-merger quality can no longer be optimal and the post-merger quality must be lower. This result cuts strongly against a US hospital merger increasing optimal quality absent a change in cost, because prices are fixed under fee-for-service Medicare and Medicaid, and because these two programs (including both the fee-for-service and the negotiated payments versions) together pay for about 55% of hospital services in the United States.

The above discussion suggests that a hospital merger is unlikely to result in improved quality absent a cost change. But a merger can result in higher quality if
it reduces the cost of producing quality. Hospital mergers sometimes have this effect, which means that clinical quality is properly a major focus of hospital merger investigations. And as discussed below, there are well-developed methods for measuring hospital quality, which makes such an analysis feasible.

On balance, the empirical evidence also does not support a strong prior that hospital mergers improve quality (see Vogt and Town, 2006, for a thorough review of this literature). Mutter et al. (2011), examined the impact of 42 consolidations involving 136 hospitals in 16 states in 1999–2000 on 25 measures of quality using DID models. Hospitals were categorized as acquiring institutions, target institutions, or participants in a “merger of equals”. Acquiring hospitals experienced significantly improved quality in terms of abdominal aortic aneurysm mortality, iatrogenic pneumothorax, and postoperative hemorrhage or hematoma, but the quality impacts for target hospitals and “mergers of equals” were mixed.

Ho and Hamilton (2000) used DID methods to test the impact of hospital consolidations in California between 1992 and 1995. Hospital consolidations had no impact on inpatient AMI or stroke mortality, although parameter estimates were imprecise. All three forms of consolidation (i.e., 21 mergers of independent hospitals, 54 independent hospitals acquired by a system, 65 acquisitions of one system by another) were associated with increased 90-day readmission rates after AMI. Only the purchase of a system hospital by another system led to earlier discharge of healthy newborns.

Cuellar and Gertler (2005) used 1995–2000 patient discharge data from Arizona, Florida, Massachusetts, and Wisconsin to estimate pre–post differences for facilities that reported joining a system during the study period. They found no significant changes in any of three composite measures of quality (i.e., mortality for 13 conditions and procedures, utilization of 3 potentially overused procedures, and 20 potential complications of inpatient care) among hospitals that joined systems, except that consolidating hospitals reduced the rate of potentially overused procedures by 1.2% among managed care patients. Finally, Gowrisankaran and Town (2003) found that competition improved quality for HMO patients, and reduced quality for Medicare patients, with the net effect being close to 0.

Although the literature does not provide support for strong priors that a given merger is likely to improve hospital quality, it is still possible that it will. Even in a retrospective case where direct evidence is available, the posterior estimate of the merger effect is influenced by evidence of the sort that would be used in a prospective merger case (including the question of “merger specificity” ). So there is value in identifying potential sources of reduced cost of providing quality and evaluating them directly. We introduce three such sources here, and defer further discussion to section 6 below. These are (1) pre-merger clinical superiority of one hospital over another, (2) economies of scale, and (3) differences in resources available for investment.

2.1.1 Clinical Superiority. One way that a merger can improve quality is if one or more of the merging hospitals is operating far below its cost/quality frontier (see Pauly, 2004), and the other(s) can move it closer. That is, a merger can improve quality at one hospital if the others have superior practices or institutions that can be readily imported. If the pre-merger management of a hospital is sufficiently ineffective, the acquiring system can achieve large gains by substituting better management.
P.S. Romano and D.J. Balan

If a merger was found likely to improve clinical quality by means of exporting superior practices, this benefit would likely require geographic proximity and therefore be merger specific, because the process of improving the inferior hospital likely requires the physical presence of personnel from the superior one.

2.1.2 Economies of Scale. Another way that a merger can improve clinical quality is through economies of scale in the provision of quality (which is distinct from economies of scale in producing output). There are some quality-improving pieces of equipment with high fixed costs and low marginal costs that are not worthwhile for an independent hospital or a small hospital system, but are worthwhile for a sufficiently large system. A merger may put the merged entity above this threshold, resulting in additional investment in quality, or the larger of the merging entities may (with little incremental cost) be able to extend to the smaller entity the benefits of investments that have already been made. Such scale economies can be a source of improved clinical quality, but may yield only marginal benefits because investments with large benefits are likely to be made even by smaller hospitals (given that standalone hospitals face the same regulations and market expectations regarding quality as multi-hospital systems). Pure system size can have a large effect on quality only if the economies of scale are correspondingly large and if the interventions that provide large economies of scale are highly clinically important. There is limited evidence of such substantial economies of scale for electronic health record systems, which are costly to implement but can yield large quality benefits due to increased portability of data across sites of care and decreased incidence of medication-related errors.

Another potential source of scale economies is surgical procedures that exhibit a volume–outcome relationship in which more repetition of the procedure generates better clinical outcomes for both individual surgeons and hospitals. This effect appears to be strong for high-risk, technically complex procedures, such as resection of esophageal cancer, pancreatic cancer, and aortic aneurysms, and inconsistent for lower-risk, more straightforward procedures such as “isolated” coronary bypass surgery and percutaneous coronary interventions. “Learning curves” have been demonstrated for technology-dependent laparoscopic procedures, whereby operator outcomes improve with accumulated experience over time. By consolidating such procedures at fewer hospitals or by sending experienced personnel from one hospital to another, a system can theoretically extend the benefits of scale enjoyed by a high-volume acquiring hospital to the acquired hospital.

Other interventions that have been shown to have substantial effects on quality can be readily implemented by hospitals of any size and are thus unlikely to be related to scale. Clinical benefits of increased scale are likely to be merger specific only if they involve consolidation of services or sharing of personnel, as these mechanisms require geographic proximity. Some interventions, such as electronic health record systems, do not require such proximity and thus cannot be considered merger specific.

2.1.3 Financial Resources. Another possible means by which a merger can improve clinical quality is via quality-improving investments that one party to the transaction (usually the acquired hospital) was previously unable to make due to lack of financial resources. The standard theory of corporate finance suggests that firms will make those investments, and only those investments, for which the present value of the net benefits, discounted at the appropriate rate, exceeds the investment...
cost, regardless of the ownership of the firm. This conclusion might fail to hold if for some reason the acquiring system has a lower cost of capital than the acquired hospital. In that case, the acquired hospital would have made those investments that were worthwhile given its original cost of capital, and the acquiring system would make additional investments that would not have been worthwhile at that cost of capital, but are worthwhile given its new, lower cost. But these incremental investments are expected to be the marginal (i.e., least valuable) investments.

Any clinical quality benefit resulting from increased financial resources will not be merger specific if there is an alternative acquirer that does not represent a competitive concern, who is willing to pay a price that the acquired hospital would accept if the merger under investigation were blocked, and who is willing to make similar investments. These conditions will be met if the investments are worthwhile on their own merit, but not if the willingness to make the investments, or even the willingness to undertake the merger, is dependent on the profits resulting from an anticompetitive price increase. The marginal value of incremental investments, combined with the likelihood that their benefits are not merger-specific, suggest that enhanced financial resources are an unlikely source of significant merger benefits.

2.2 Health Effects of Higher Prices for Health Insurance

Even if our analysis had found a merger-specific quality increase at the merging hospitals, the indirect effect of a price-increasing merger on health must still be considered. Higher hospital prices cause health insurance premiums to increase, which causes some people to lose or forego insurance. Town et al. (2006) estimated that in 2003 there were 695,000 fewer insured people in the United States than there would have been had there been no hospital merger activity in the 1990s. There is a substantial literature showing that lack of insurance harms health, and may be responsible for 18,000–22,000 premature deaths each year in the United States, although this estimate has recently been challenged by Kronick (2009). This harm would not be realized at the merging hospitals, as the people who lose their insurance would not necessarily have used the merging hospitals (or any hospital). The magnitude of this effect is difficult to quantify, as it would require estimating the insurance premium increase resulting from the hospital price increase, the number of people who would lose their insurance as a result of that premium increase, and the health harm accruing to people who lost their insurance. But the effect is present, and it means that any measured health benefit at the merging hospitals represents an upper bound on the total beneficial effect of the merger on health. Because of the absence of demonstrable quality improvement in the ENH/HPH case, it was not necessary for us to address this question.

3. Data, Quality Measures, and Empirical Methodology

3.1 Data

Our data source is the Illinois Department of Public Health (IDPH) Universal Dataset. This data set contains all inpatient discharges from non-federal acute care hospitals in Illinois from 1998–2003. It contains information on the demographic characteristics of each patient, as well as ICD-9-CM (International Classification of Diseases, 9th Revision, Clinical Modification) diagnosis and procedure codes that
describe the clinical condition of each patient and what procedures were performed. In preparation for trial, we also analyzed specialty-specific patient outcomes data from the National Registry of Myocardial Infarction, the Society for Thoracic Surgeons, and the National Perinatal Information Center, as well as patient satisfaction and experience data from the vendor Press Ganey. Hospitals voluntarily submit their data to these organizations and programs, and then receive benchmarking reports describing their performance in comparison with other facilities. The merging parties were required to provide these reports for review and analysis, and they were used in the first author’s testimony, but they belong to the merging parties and therefore are not available to report here.

3.2 Quality Measures

The primary quality measures analyzed in this paper come from Version 2.1 of the Inpatient Quality Indicators (IQIs) and the Patient Safety Indicators (PSIs) developed by the Agency for Healthcare Research and Quality (AHRQ). These indicators of health-care quality make use of hospital inpatient administrative data such as the IDPH data, and focus principally on short-term patient outcomes. The IQIs reflect quality of care inside hospitals, including inpatient mortality for medical conditions and surgical procedures, and the PSIs focus on potentially avoidable complications and iatrogenic events. To implement these measures, we ran the data obtained from the IDPH through a commercial “grouper” software program that used each patient’s demographic information, diagnosis codes, and procedure codes to assign that patient to an “All Patient Refined Diagnosis Related Group” (APR-DRG) and to a Risk of Mortality (ROM) subclass. We then fed these APR-DRGs and ROMs, along with other elements from the IDPH dataset, into AHRQ’s publicly available Quality Indicator software for SAS to generate risk-adjusted outcomes measures. IQI risk adjustment incorporates age, gender, age–gender interactions, circumstances of admission (i.e., transfer from another hospital), and APR-DRGs with ROM subclasses. PSI risk adjustment incorporates age, gender, age–gender interactions, circumstances of admission, base DRGs (i.e., aggregated across comorbidity/complication levels), and AHRQ-defined comorbidities.14

The other quality measures that we used were developed by the Joint Commission on Accreditation of Healthcare Organizations, now known as The Joint Commission (TJC). TJC is the largest accrediting organization for acute care hospitals in the United States; its accreditation review process includes a broad array of Core Measures that hospitals are required to collect and report. TJC maintains measures of risk-adjusted mortality for heart attack patients, neonatal mortality, and obstetric trauma. We purchased these measures (which are now publicly available on Medicare’s HospitalCompare website but which were not at the time) from a leading vendor (Iameter).

All of the analyses described in this paper involve patient outcomes. This is an appropriate focus, as outcomes are of ultimate interest to patients, their families, and policy makers. However, data limitations make it difficult to judge a hospital solely on its outcomes. This is partly because hospitals often have a relatively small number of patients of a given type, which makes outcomes a noisy measure of quality, and partly because there are many outcomes that cannot be measured at all with available data, such as post-hospitalization mortality, quality of life, and functional status. For this reason, hospital quality researchers also use
“structural” quality measures, which focus on whether organizations have the human resources and technical infrastructure to provide high-quality care, and “process” measures, which focus on the specific diagnostic and therapeutic services that organizations provide. At trial, the first author discussed several of these measures, but we do not discuss them here as they mostly relied on proprietary data obtained from the merging parties. For this reason, the results reported below are confined to outcomes measures from AHRQ and TJC, which represented the core of our analysis.

3.3 Empirical Methodology

Our empirical methodology involves a series of DID analyses of risk-adjusted mortality and complication rates for a number of clinical conditions. We evaluate whether the changes in these rates at the merged hospitals were different from the changes at a set of control hospitals. Changes in the control-group rates serve as a counterfactual proxy for what the changes would have been at the merging hospitals absent the merger.

The virtue of DID analysis is that confounding factors that do not vary over time (i.e., hospital fixed effects) are “differenced out”. If the case mix of each hospital’s patients did not change from year to year, then any differences in patient severity of illness would also be differenced out, and there would be no problem using raw mortality and complication rates in the analysis. But patient mix can change over time, particularly following a merger that may alter referral practices in the community, leading to differential changes in hospitals’ case mixes. For this reason, we prefer to do the analysis using risk-adjusted mortality and complication rates, which are interpreted as the rate that a hospital would have had if its patients were of average severity. Even with the risk adjustment, we recognize that some confounding is likely to persist due to omitted clinical factors.

The disadvantage of using risk-adjusted rather than raw rates is that risk-adjusted rates depend to some extent on hospitals’ reporting practices. That is, when assigning diagnosis and procedure codes to patients, hospital coders rely upon physician documentation combined with their own professional experience and judgment. Changes in these coding practices over time may confound the DID exercise. However, these coding practices seem less likely to change differentially over time (after a merger) than patient severity, which is why we emphasize risk-adjusted rates while also reporting raw rates.

Following Haas-Wilson and Garmon (2011), we performed our analysis using four different control groups. The first group consisted of all non-federal general acute care hospitals in the Chicago Primary Metropolitan Statistical Area (PMSA). The purpose of using hospitals in the Chicago area as controls is that these hospitals likely had cost and demand experiences that were similar to those affecting the merging hospitals. Control hospitals selected from elsewhere may have had different experiences, which would confound the analysis. The other three control groups consisted of subsets of the Chicago Primary Metropolitan Statistical Area hospitals that arguably were particularly similar to the hospitals in the ENH system. Since the other three control groups generated very similar results, we only report results using the first group.

The merger occurred in early 2000. We omit 2000 as a transition year, as any merger-induced changes would take some time to be implemented. We define the pre-merger period as 1998–1999, and the post-merger period as 2001–2003. Our
primary concern is with changes in clinical quality at HPH, as it is at HPH that Respondent’s Counsel claimed the merger improved quality. However, it is also possible that the merger could have had effects on clinical quality at Evanston Hospital and/or Glenbrook Hospital, as resources may have been diverted from Evanston or Glenbrook to Highland Park in such a way that Highland Park’s gain was Evanston’s or Glenbrook’s loss. This effect is most likely to be present for cardiac services because ENH started a new cardiac surgery and interventional cardiology program at HPH, and the resources for that program were drawn largely from Evanston and Glenbrook. To simplify the presentation, we report only analyses on HPH and Evanston Hospital, but these results are not materially affected by adding Glenbrook Hospital.

We define our DID estimator as \( \beta = \Delta p_{\text{enh}} - \Delta p_{\text{control}} \). Under the assumption of i.i.d. random sampling from a binomial distribution, the standard error of \( \beta \) is the denominator of the expression below. Therefore the following is (approximately) distributed standard normal under the null hypothesis that quality at ENH did not change relative to the control group:

\[
Z = \frac{\left( p_{\text{enh}}^{\text{post}} - p_{\text{enh}}^{\text{pre}} \right) - \left( p_{\text{control}}^{\text{post}} - p_{\text{control}}^{\text{pre}} \right)}{\sqrt{\frac{p_{\text{enh}}^{\text{post}} (1 - p_{\text{enh}}^{\text{post}})}{N_{\text{enh}}^{\text{post}}} + \frac{p_{\text{enh}}^{\text{pre}} (1 - p_{\text{enh}}^{\text{pre}})}{N_{\text{enh}}^{\text{pre}}} + \frac{p_{\text{control}}^{\text{post}} (1 - p_{\text{control}}^{\text{post}})}{N_{\text{control}}^{\text{post}}} + \frac{p_{\text{control}}^{\text{pre}} (1 - p_{\text{control}}^{\text{pre}})}{N_{\text{control}}^{\text{pre}}}}
\]

where \( p \) represents the probability of the adverse outcome (death or complication) and \( N \) represents the number of patients.

4. Results

The analyses that we performed were chosen in response to specific quality claims made by Respondent’s Counsel. In this section, we discuss those claims, how we determined which quality measures were appropriate for testing them, and the results of the tests. As described above, we calculate the pre–post-merger absolute (percentage point) differences at the treatment hospitals, and then calculate those differences between those and the absolute differences at the control hospitals. We report both risk-adjusted and raw rates, which are similar in most cases.

4.1 Cardiac Surgery and Interventional Cardiology

After the merger, ENH established cardiac surgery and interventional cardiology programs at HPH, so that coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) procedures began to be performed there. Since there was no such program at HPH before the merger, no pre- vs. post-merger comparison is possible. But it is possible that the establishment of the program at HPH had an adverse impact on Evanston Hospital, as resources may have been diverted to support the new program at HPH.\(^1^7\) To test this hypothesis, we analyzed the CABG and PCI mortality Inpatient Quality Indicators (IQIs) at Evanston Hospital. Results are reported in Table 1.

For CABG, the control hospitals experienced a 0.80% absolute reduction in risk-adjusted mortality, and EH experienced a 0.56% increase, for a DID of 1.37%. For PCI, the decrease at the control hospitals was 0.11% and the increase at EH was
0.54%, for a DID of 0.65%. Both of these estimates are in the direction of a quality reduction, although neither is statistically significant. In both cases, the effects are smaller (but in the same direction) for the raw rates than for the risk-adjusted rates.

4.2 Advantages of Teaching Hospitals

There is evidence that teaching hospitals tend to outperform non-teaching hospitals in caring for inpatients with a variety of conditions, including acute myocardial infarction (AMI, or heart attack), congestive heart failure (CHF), pneumonia, and stroke. Respondent’s Counsel claimed that the merger allowed HPH to realize the advantages of a teaching hospital. Based on publicly available data, the first author argued that neither EH nor HPH met the definition of a teaching hospital, as defined in most prior studies (i.e., membership in the Council of Teaching Hospitals or at least 0.10–0.27 residents per bed). Nevertheless, we tested the claim by analyzing the AHRQ Inpatient Quality indicators for those four conditions, as well as the corresponding TJC indicator for AMI. Results are reported in Table 2.

According to the IQI measure, risk-adjusted AMI mortality at the control hospitals decreased by 1.88%, and increased at HPH by 0.34%, for a DID of 2.22%. This finding suggests a decrease in quality at HPH, but is not statistically significant. However, for this measure there is an unusually large divergence between the risk-adjusted result and the raw DID of −3.21% (also not statistically significant). Both the risk-adjusted and raw rates show a large and statistically significant decrease in quality at EH, with DID of 4.46% and 3.33% respectively.

According to the TJC measure, risk-adjusted AMI mortality decreased by 1.52% at the control hospitals (compared to 1.88% according to the IQI measure), and decreased by 5.01% at HPH (compared to an increase of 0.34% according to the IQI measure), for a non-significant DID of −3.48%. Similarly, the DID at Evanston is −0.59%, as compared to an increase of 4.46% for the IQI measure. These differences may be partially explained by differences in risk adjustment, and also by the exclusion of patients who were transferred in from other hospitals (as well as out-transfers) from the TJC measure; by contrast, the AHRQ measure only excludes out-transfers, because it is not known whether they survived the acute hospital stay. However, the discrepancy is large enough to cause us to suspect that there may have been a coding error in the commercial software that we used to group the APR-DRGs, in the AHRQ IQI software, or in the software used by Iameter to calculate the TJC measures.

CHF mortality improved non-significantly at both HPH (risk-adjusted DID of −1.60%) and EH (−0.19%) after the merger. Risk-adjusted and raw pneumonia mortality and stroke mortality deteriorated non-significantly at HPH (risk-adjusted DID of 0.30% for pneumonia and 2.42% for stroke). There was also a large and statistically significant deterioration in risk-adjusted pneumonia (3.14%) and stroke (4.94%) mortality at Evanston Hospital.

4.3 Nursing-Sensitive Indicators

Another claim made by Respondent’s Counsel was that the merger improved nursing care at HPH. We evaluate this claim by examining Patient Safety Indicators that are known to be sensitive to the quality of nursing care, and that reflect concepts endorsed by the National Quality Forum (NQF) as voluntary consensus
### Table 1. Quality Indicators for Cardiac Services

<table>
<thead>
<tr>
<th></th>
<th>Control Hospitals</th>
<th>Highland Park Hospital</th>
<th>Evanston Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-merger rate (%)</td>
<td>Post-merger rate (%)</td>
<td>Pre-merger rate (%)</td>
</tr>
<tr>
<td>Coronary Artery Bypass Graft (raw) AHRQ</td>
<td>4.15% (0.25%)</td>
<td>4.00% (0.22%)</td>
<td>6,379</td>
</tr>
<tr>
<td>Coronary Artery Bypass Graft (risk adjusted) AHRQ</td>
<td>3.90% (0.24%)</td>
<td>3.10% (0.19%)</td>
<td>7,945</td>
</tr>
<tr>
<td>Percutaneous Coronary Intervention (raw) AHRQ</td>
<td>1.79% (0.13%)</td>
<td>1.54% (0.10%)</td>
<td>9,715</td>
</tr>
<tr>
<td>Percutaneous Coronary Intervention (risk adjusted) AHRQ</td>
<td>1.34% (0.12%)</td>
<td>1.23% (0.09%)</td>
<td>16,840</td>
</tr>
</tbody>
</table>

**Notes:**


b. For each measure, the pre-merger sample size is shown in the row labeled “raw”; the post-merger sample size is shown immediately underneath in the row labeled “risk adjusted”.

c. Standard errors in parentheses.

d. One, two and three stars represent statistical significance at the 10%, 5%, and 1% levels, respectively.

e. Highland Park Hospital did not perform coronary artery bypass grafts or percutaneous coronary interventions prior to the merger.

AHRQ denotes a quality measure developed and disseminated by the Agency for Healthcare Research and Quality.
### Table 2: Quality Indicators Reflecting Advantages of Teaching Hospitals

<table>
<thead>
<tr>
<th></th>
<th>Control Hospitals</th>
<th>Highland Park Hospital</th>
<th>Evanston Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-merger rate (%)</td>
<td>Post-merger rate (%)</td>
<td>Sample Size</td>
</tr>
<tr>
<td>Acute Myocardial Infarction (raw) AHRQ</td>
<td>9.44% (0.36%)</td>
<td>7.42% (0.26%)</td>
<td>6,726</td>
</tr>
<tr>
<td>Acute Myocardial Infarction (risk-adjusted) AHRQ</td>
<td>10.09% (0.37%)</td>
<td>8.21% (0.27%)</td>
<td>10,415</td>
</tr>
<tr>
<td>Acute Myocardial Infarction (raw) TJC</td>
<td>9.86% (0.40%)</td>
<td>7.57% (0.28%)</td>
<td>5,644</td>
</tr>
<tr>
<td>Acute Myocardial Infarction (risk-adjusted) TJC</td>
<td>10.54% (0.41%)</td>
<td>9.02% (0.30%)</td>
<td>8,916</td>
</tr>
<tr>
<td>Congestive Heart failure mortality (raw) AHRQ</td>
<td>4.13% (0.18%)</td>
<td>3.79% (0.13%)</td>
<td>11,828</td>
</tr>
<tr>
<td>Congestive Heart failure mortality (risk-adjusted) AHRQ</td>
<td>4.35% (0.19%)</td>
<td>3.33% (0.13%)</td>
<td>20,043</td>
</tr>
<tr>
<td>Pneumonia mortality (raw) AHRQ</td>
<td>9.24% (0.25%)</td>
<td>8.18% (0.20%)</td>
<td>13,827</td>
</tr>
<tr>
<td>Pneumonia mortality (risk-adjusted) AHRQ</td>
<td>8.83% (0.24%)</td>
<td>7.62% (0.19%)</td>
<td>17,997</td>
</tr>
<tr>
<td>Stroke mortality (raw) AHRQ</td>
<td>10.66% (0.39%)</td>
<td>10.83% (0.31%)</td>
<td>6,284</td>
</tr>
<tr>
<td>Stroke mortality (risk-adjusted) AHRQ</td>
<td>10.53% (0.39%)</td>
<td>9.42% (0.29%)</td>
<td>10,033</td>
</tr>
</tbody>
</table>

**Notes:**


b. For each measure, the pre-merger sample size is shown in the row labeled “raw”; the post-merger sample size is shown immediately underneath in the row labeled “risk adjusted”.

c. Standard errors in parentheses.

d. One, two and three stars represent statistical significance at the 10%, 5%, and 1% levels, respectively.

AHRQ denotes a quality measure developed and disseminated by the Agency for Healthcare Research and Quality.

TJC denotes a quality measure developed and employed by The Joint Commission.
standards for nursing-sensitive care. These include Decubitis Ulcers (pressure sores), Failure to Rescue (death among surgical patients with potentially serious but treatable in-hospital complications), Selected Infections due to Medical Care, and Post-operative Hip Fracture. Results are reported in Table 3.

HPH experienced slight post-merger deterioration for Post-operative Hip Fracture (DID in risk-adjusted rates of 0.10%), and improvements in the other three indicators (a statistically significant −0.76% for Decubitis Ulcer and non-significant −2.74% for Failure to Rescue and −0.01% for Selected Infections due to Medical Care). However, for Decubitis Ulcer and Failure to Rescue, the raw DID are much smaller in magnitude, and in the case of Failure to Rescue, it is of the opposite sign. The results for EH are mixed, with several nursing-sensitive PSIs showing statistically significant improvements.

4.4. Obstetrics

Another quality claim made by the Respondent’s Counsel was that the merger had improved obstetric care at HPH. We evaluated this claim by examining the three PSIs that relate to obstetrics: Birth Trauma, Obstetric Trauma (vaginal with instrument), and Obstetric Trauma (vaginal without instrument). We also examine all three of the TJC obstetrics measures: Obstetric Trauma, Neonatal Mortality, and Vaginal Birth after Cesarean (VBAC). Note that VBAC is not considered to be a quality measure in the traditional sense, but it reflects whether a hospital is capable of providing patient-centered care to women who have had prior cesarean deliveries. Results are reported in Table 4.

For the risk-adjusted obstetric PSI measures, results at HPH were unfavorable, with statistically significant deteriorations of 0.33% for Birth Trauma and 1.28% for Obstetric Trauma (vaginal without instrument), and a non-significant deterioration of 3.76% for Obstetric Trauma (vaginal with instrument). EH deteriorated on all three obstetric indicators, and the deterioration was statistically significant for Birth Trauma and Obstetric Trauma (vaginal with instrument).

For the risk-adjusted TJC measures, HPH had a non-significant DID of 0.12% for neonatal mortality and a statistically significant DID of −1.14% for obstetric trauma. EH had statistically significant DIDs of −1.08% for obstetric trauma and of 0.32% for neonatal mortality.

5. Discussion

The above results do not support the claim that quality improved substantially at HPH as a result of the merger. While the relatively small number of patients at HPH means that our statistical tests have limited power, the point estimates mostly suggest a modest deterioration relative to the control group. Given that the literature (as discussed above) does not support strong prior beliefs that the merger would improve quality, our posterior belief is that the merger is unlikely to have improved quality sufficiently to outweigh its harmful effects. These results highlight the importance of evaluating hospital merger claims on a case-by-case basis.

Our results must be interpreted with caution. As can be seen in the tables, the standard errors on the HPH DID estimates are generally quite large. So in many instances where the point estimate indicates a relative deterioration, substantial improvement cannot be ruled out. Also, each quality measure is
Table 3. Nursing-Sensitive Quality Indicators

<table>
<thead>
<tr>
<th>Measure</th>
<th>Control Hospitals</th>
<th>Highland Park Hospital</th>
<th>Evanston Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decubitis Ulcers (raw) AHRQ</td>
<td>2.02% (0.04%)</td>
<td>2.31% (0.03%)</td>
<td>2.02% (0.13%)</td>
</tr>
<tr>
<td></td>
<td>2.13% (0.03%)</td>
<td>1.99% (0.17%)</td>
<td>1.99% (0.11%)</td>
</tr>
<tr>
<td>Decubitis Ulcers (risk adjusted) AHRQ</td>
<td>2.22% (0.04%)</td>
<td>2.39% (0.03%)</td>
<td>2.22% (0.13%)</td>
</tr>
<tr>
<td></td>
<td>2.31% (0.03%)</td>
<td>1.99% (0.15%)</td>
<td>1.99% (0.10%)</td>
</tr>
<tr>
<td>Failure to Rescue (raw) AHRQ</td>
<td>12.21% (0.27%)</td>
<td>11.03% (0.19%)</td>
<td>12.21% (0.13%)</td>
</tr>
<tr>
<td></td>
<td>9.82% (1.99%)</td>
<td>9.23% (1.28%)</td>
<td>9.82% (1.83%)</td>
</tr>
<tr>
<td>Failure to Rescue (risk adjusted) AHRQ</td>
<td>11.41% (0.26%)</td>
<td>9.81% (0.18%)</td>
<td>11.41% (0.26%)</td>
</tr>
<tr>
<td></td>
<td>9.79% (1.99%)</td>
<td>5.45% (1.01%)</td>
<td>9.79% (1.99%)</td>
</tr>
<tr>
<td>Selected Infections Due to Medical Care (raw) AHRQ</td>
<td>0.26% (0.01%)</td>
<td>0.29% (0.01%)</td>
<td>0.26% (0.02%)</td>
</tr>
<tr>
<td></td>
<td>0.08% (0.03%)</td>
<td>0.11% (0.02%)</td>
<td>0.08% (0.03%)</td>
</tr>
<tr>
<td>Selected Infections Due to Medical Care (risk adjusted) AHRQ</td>
<td>0.25% (0.01%)</td>
<td>0.21% (0.01%)</td>
<td>0.25% (0.01%)</td>
</tr>
<tr>
<td></td>
<td>0.13% (0.03%)</td>
<td>0.08% (0.02%)</td>
<td>0.13% (0.03%)</td>
</tr>
<tr>
<td>Post-Operative Hip Fracture (raw) AHRQ</td>
<td>0.11% (0.01%)</td>
<td>0.07% (0.01%)</td>
<td>0.11% (0.01%)</td>
</tr>
<tr>
<td></td>
<td>0.11% (0.01%)</td>
<td>0.19% (0.07%)</td>
<td>0.11% (0.01%)</td>
</tr>
<tr>
<td>Post-Operative Hip Fracture (risk adjusted) AHRQ</td>
<td>0.12% (0.01%)</td>
<td>0.01% (0.00%)</td>
<td>0.12% (0.01%)</td>
</tr>
<tr>
<td></td>
<td>0.10% (0.07%)</td>
<td>0.10% (0.05%)</td>
<td>0.10% (0.07%)</td>
</tr>
</tbody>
</table>

Notes:

b. For each measure, the pre-merger sample size is shown in the row labeled “raw”; the post-merger sample size is shown immediately underneath in the row labeled “risk adjusted”.
c. Standard errors in parentheses.
d. One, two and three stars represent statistical significance at the 10%, 5%, and 1% levels, respectively.

AHRQ denotes a quality measure developed and disseminated by the Agency for Healthcare Research and Quality.
<table>
<thead>
<tr>
<th>Table 4. Obstetric Quality Indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Birth Trauma to Newborn Infants</td>
</tr>
<tr>
<td>(raw) AHRQ</td>
</tr>
<tr>
<td>Birth Trauma to Newborn Infants</td>
</tr>
<tr>
<td>(risk adjusted) AHRQ</td>
</tr>
<tr>
<td>Obstetric Trauma (Vaginal with</td>
</tr>
<tr>
<td>Instrument) (raw) AHRQ</td>
</tr>
<tr>
<td>Obstetric Trauma (Vaginal with</td>
</tr>
<tr>
<td>Instrument) (risk adjusted) AHRQ</td>
</tr>
<tr>
<td>Obstetric Trauma (Vaginal without</td>
</tr>
<tr>
<td>Instrument) (raw) AHRQ</td>
</tr>
<tr>
<td>Obstetric Trauma (raw) TJC</td>
</tr>
<tr>
<td>(risk adjusted) TJC</td>
</tr>
<tr>
<td>Vaginal Birth after Caesarian (raw)</td>
</tr>
<tr>
<td>TJC</td>
</tr>
</tbody>
</table>
Table 4. (Continued)

<table>
<thead>
<tr>
<th></th>
<th>Control Hospitals</th>
<th>Highland Park Hospital</th>
<th>Evanston Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-merger rate (%)</td>
<td>Post-merger rate (%)</td>
<td>Sample Size</td>
</tr>
<tr>
<td>Vaginal Birth after Caesarian (risk-adjusted) TJC</td>
<td>21.05% (0.51%)</td>
<td>21.29% (0.38%)</td>
<td>11,427</td>
</tr>
<tr>
<td>Neonatal Mortality (raw) TJC</td>
<td>1.08% (0.04%)</td>
<td>0.80% (0.03%)</td>
<td>53,739</td>
</tr>
<tr>
<td>Neonatal Mortality (risk-adjusted) TJC</td>
<td>1.09% (0.04%)</td>
<td>0.85% (0.03%)</td>
<td>108,588</td>
</tr>
</tbody>
</table>

Notes:

b. For each measure, the pre-merger sample size is shown in the row labeled “raw”; the post-merger sample size is shown immediately underneath in the row labeled “risk adjusted”.
c. Standard errors in parentheses.
d. One, two and three stars represent statistical significance at the 10%, 5%, and 1% levels, respectively.
AHRQ denotes a quality measure developed and disseminated by the Agency for Healthcare Research and Quality.
TJC denotes a quality measure developed and employed by The Joint Commission.
tested for statistical significance individually, which means that some results may spuriously appear significant by chance. Given the risk of making at least one type 1 error, the overall pattern of the findings is more important than any specific finding of significance or non-significance. The statistical significance of some findings may also be overstated because we did not account for heterogeneity among control hospitals. We also cannot exclude the possibility of endogeneity; a decision to merge may reflect hospital managers’ inside knowledge of emerging trends in quality, such that the experience of control hospitals may not represent what would have happened at the merging hospitals but for the merger. Finally, selecting control hospitals from the same metropolitan area offers the advantage of adjusting for unmeasured environmental factors that affect hospital quality (e.g., local resources for uncompensated care, Medicaid payment rates, regulations regarding physician or hospital licensure), but it may lead to underestimation of merger impact if control hospitals in the same market respond to diminished competition by reducing quality.

6. Applicability to Prospective Merger Analysis

This paper has focused on retrospective evaluation of the ENH/HPH case. But the great majority of merger cases are prospective in nature, where the objective is to predict the effects of the merger, rather than to measure them after the fact. A recent example is the proposed acquisition of Prince William Hospital in Manassas, Virginia, by the Inova Health System. It is therefore worth discussing what kind of analysis of clinical quality is possible in such cases.

In section 2.1 above, we argue that a merger is unlikely to cause an increase in quality absent a reduction in the cost of producing quality, and so a finding that those costs did not decrease is likely sufficient to show that the merger will not improve quality. The quality analysis in a prospective case focuses on ways in which the merger is likely to reduce the cost of producing quality, whether by means of a superior hospital exporting its knowledge and practices to an inferior one, through economies of scale, or as a result of differences in financial resources. Quality claims regarding clinical superiority and economies of scale can sometimes be investigated directly. The likelihood of an improvement as a result of clinical superiority is greater if there are specific quality-improving measures that have been adopted by the acquiring system and for which there are concrete plans to export them following the merger. Similarly, improvements due to economies of scale are unlikely if a hospital targeted for acquisition does not actually perform the most volume-sensitive procedures, or if it has already reached a plateau on the learning curve for technology-dependent procedures.

A less direct but still valuable way to evaluate the likely quality effects of a merger is to compare pre-merger quality levels at all of the facilities involved in the merger. Large and consistent differences in these levels constitute evidence that the target hospital is underperforming and/or that the acquiring hospital is enjoying significant economies of scale relative to the acquiring system, providing potential opportunities for post-acquisition improvement. For example, Keroack et al. (2007) showed substantial variation in quality among academic health systems of similar size, which was linked to variation in management and organizational culture, and Jha et al. (2003) showed how the Veterans Health Administration used superior management to improve clinical quality and reduce intra-system variation in quality. Comparison of pre-merger quality
trends may also be of some value, but can be misleading because trends may not persist, particularly if one hospital started with a much lower level of clinical performance. Large pre-merger differences in quality levels are neither necessary nor sufficient for a merger to result in a quality increase. It is possible that a superior acquiring hospital will fail to improve an inferior one, and it is also possible that one hospital can improve another even if it is not superior. Nevertheless, pre-merger quality differences suggest that one hospital has something of value to impart to the other, absent evidence to the contrary, such as prior failure to improve performance at a previously acquired hospital.

It is worth noting that in a retrospective DID analysis, any variation across hospitals in coding practices or in patient severity that is not fully captured by risk adjustment will not confound the analysis as long as these differences do not vary over time. In a prospective analysis, such differences in coding practices or patient severity will confound the analysis. For example, a hospital with particularly aggressive coding practices will have patients that appear sicker, and so its performance will appear better even when it really is not. So an important part of any prospective analysis is to gather as much evidence as possible regarding between-hospital variation in baseline severity of illness and coding practices.

7. Conclusions

There is considerable evidence that hospital mergers can cause substantial price increases. These price increases could in principle be counterbalanced by pro-competitive effects, the most important of which is improved clinical quality. In this paper, we describe the methodology that we used in the ENH/HPH merger case. We used a straightforward DID methodology to determine whether the merger resulted in improved performance on a variety of clinical outcomes measures (risk-adjusted inpatient death and complications). We find little evidence that the merger caused quality to improve at Highland Park.

On the basis of these findings, the Administrative Law Judge found “no evidence of improvement in overall quality of care relative to other hospitals.” We believe that the basic framework for analyzing the clinical quality effect of mergers will be applicable to future cases, including prospective ones. There are plausible mechanisms through which a merger can cause a substantial quality improvement, which means that there may be some otherwise problematic mergers whose harmful effects are offset by improved quality. While we take no position on how price and quality should be traded off against each other when they are in conflict, our methodological approach will generate a general picture of the magnitude of any quality effect, which can then be weighed against the predicted price effect in the manner deemed appropriate by the decision maker.

Notes

1. Dr. Haas-Wilson estimated that ENH’s inpatient price increased 11.1 to 17.9 percentage points more than the price at various control groups after the merger. See In Re Evanston Northwestern Healthcare Corp., Dkt. No. 9315, slip op. at 35 (Aug. 6, 2007) (opinion of the Commission). Available at: http://www.ftc.gov/os/adipro/d9315/070806opinion.pdf. Respondent’s expert Dr. Jonathan Baker estimated that ENH’s inpatient price increased 9 to 10 percentage points more than at his control group after the merger. Id at 38.

3. Many hospitals, including ENH, are not-for-profit (NFP). There is limited evidence that NFP hospitals tend to have somewhat higher clinical quality (see Devereaux et al., 2002; Eggleston et al., 2008; Picone et al., 2002; Shen, 2002; and Farsi, 2004), but we are aware of no evidence that NFP and FP hospitals differ in their quality response to mergers. NFP hospitals might reinvest a larger fraction of the gains from competition-reducing mergers, but we are aware of no direct evidence on this question either. The quality effect of any such additional spending will depend on the pre-merger condition of the acquired hospital and on the specific investments chosen by managers of the merged entity. If the merging hospitals already had adequate resources, then additional expenditures will likely only generate small incremental benefits.


5. To justify an otherwise anticompetitive merger, an improvement in quality would not only need to be demonstrable, but would also need to be “merger specific”, meaning that it would only be realized through that particular merger, and not by any other means, such as an alternative merger that does not pose competitive concerns. So even a clinical quality improvement large enough to counterbalance the price effect of a merger would not necessarily justify the merger; it would be necessary to show that a sufficiently large portion of those quality benefits would not have been realized any other way. Quality analysis is only relevant for mergers that are expected to cause price increases (otherwise the quality issue will never be reached), and price-increasing mergers usually involve hospitals that are geographically proximate, so past or future quality improvements are unlikely to qualify as merger-specific unless they require a geographically proximate merger partner. Since there was little meaningful evidence of quality improvement in the ENH/HPH case, the merger specificity issue was not a major one.

6. Note that the relevant issue is the size of the system, not the size of the individual hospital. Mergers typically do not affect the size of the individual hospitals, so hospital-level economies of scale are not relevant.

7. The role of multihospital system membership in electronic medical record adoption was explored by Li et al. (2008). The quality benefit of an electronic medical record with computerized physician order entry and decision support features was first demonstrated by Bates et al. (1998).

8. See Halm et al. (2002), Killeen et al. (2005), and the report of the ECRI Institute (2010).


10. It is also possible that the acquiring system may find it impossible to transfer its scale economies to an acquired hospital. For example, if local factors preclude shutting down a low-volume but technically complex service, or if transferring personnel across facilities is not feasible, then quality may not improve post-merger at the acquired hospital. Therefore, it cannot be assumed that any merger will lead to economies of scale related to the quality of technically complex procedures.

11. See Pronovost et al. (2006), Pronovost et al. (2010), Haynes et al. (2009), and Weiser et al. (2010).

12. It is conceivable that an electronic health record system involving geographically proximate hospitals may confer greater quality benefits than an equivalent system involving non-proximate hospitals, by allowing patients to obtain coordinated care from multiple local facilities, but this hypothesis has never been empirically tested.

13. The estimate of 18,000 comes from the Institute of Medicine (2002); the higher estimates come from Dorn (2008).


16. The other three control groups were all non-federal general acute care hospitals in the Chicago PMSA that: (1) were not involved in a merger between 1996 and 2002; (2) had residency programs at the time of the merger; and (iii) had more than 0.25 residents and interns per staffed bed between 1998 and 2002.
17. It is also possible that the existence of the programs at HPH improved access to those services, and thereby improved cardiac health in the broader community. We investigated this question and found no such evidence, and so we do not report those results here.

18. See Ayanian and Weissman (2002) for an excellent summary of this literature, including description of various definitions of teaching hospitals that have been used in 20 published studies.

19. Post-Trial Brief of Respondent, supra at 93; and Respondent’s Corrected Appeal Brief, supra at 4.

20. Post-Trial Brief of Respondent, supra at 83; and Respondent’s Corrected Appeal Brief, supra at 12.

21. See http://www.qualityforum.org/Projects/n-r/Nursing-Sensitive_Care_Initial_Measures/Nursing_Sensitive_Care__Initial_Measures.aspx

22. Post-Trial Brief of Respondent, supra at 75; and Respondent’s Corrected Appeal Brief, supra at 12.

23. With respect to obstetric trauma, the TJC indicator includes both types of vaginal deliveries (with and without instrumentation), whereas the AHRQ indicator stratifies them to create two separate indicators. In addition, in the version of the AHRQ Quality Indicators software that we used in this analysis (Version 2.1), the numerator definition was somewhat different than that in the TJC indicator, capturing high vaginal and cervical trauma but excluding third-degree perineal lacerations.

24. Several results suggest deterioration at Evanston Hospital as well, with the notable exception of some nursing-sensitive indicators. The larger sample sizes at Evanston Hospital mean that the tests have more power, and so more results achieve statistical significance. However, it is not clear that this deterioration was a result of the merger with HPH. It is possible that the merger harmed EH through diversion of resources or lack of focus, but it is also possible that the deterioration had some other cause.

25. In contrast, there is no direct link between pre-merger price levels and the price effects of mergers, so a comparison of pre-merger pricing would not be informative.


References


